Jens Ruhe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jens ruhe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jens Ruhe Today - Breaking & Trending Today

SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimm

MUNICH, Germany, November 15, 2023 / B3C newswire / SciRhom GmbH, a pioneering biotech enterprise specialized in developing first-in-class therapeutic antibodies, announced today the achievement of a significant milestone in its development pipeline. The company has submitted a Clinical Trial Application for its. ....

Jan Poth , Jens Ruhe , Scirhom Gmb , Scirhom Gmbh , Clinical Trial Application , Managing Director , Wuxi Biologics , Rhom Gmbh , Special Surgery , High Tech Gruenderfonds , Autoimmune Diseases , Tumor Necrosis Factor Alpha , Intracellular Signaling Peptides , Signal Transduction , Erbb Receptors , Lupus Nephritis , Inflammatory Bowel Diseases , Pharmaceutical Preparations , Biological Products ,

SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimmune Diseases

MUNICH, Germany, November 15, 2023 / B3C newswire / SciRhom GmbH, a pioneering biotech enterprise specialized in developing first-in-class therapeutic antibodies, announced today the achievement of a significant milestone in its development pipeline. The company has submitted a Clinical Trial Application for its. ....

Jan Poth , Scirhom Gmb , Jens Ruhe , Scirhom Gmbh , Clinical Trial Application , Managing Director , Wuxi Biologics ,

SciRhom Announces Addition to the Management Team

To optimize management expertise for the next phase of development, Dr. Jan Poth will assume the role of Chief Executive Officer in advancing the company’s proprietary anti-iRhom2 antibodies.MUNICH, Germany, May 12, 2022 / B3C newswire / SciRhom GmbH, a therapeutic antibody developer, announced today that Dr. Jan. ....

Scirhom Gmb , Jan Poth , Boehringer Ingelheim , Jens Ruhe , Chief Executive Officer , Scirhom Gmbh , Chief Executive , Chief Operating , Therapeutic Area Head Immunology , Chief Operating Officer , Rhom Gmbh , Special Surgery , High Tech Gruenderfonds , Autoimmune Diseases , Tumor Necrosis Factor Alpha , Intracellular Signaling Peptides , Signal Transduction , Lupus Erythematosus , Inflammatory Bowel Diseases , Pharmaceutical Preparations , Biological Products ,

SciRhom Augments Seed Financing to Reach Total Funding of EUR 16 Million

The increased investment accelerates SciRhom’s roadmap towards IND approval for their first-in-class drug candidates, which promise significant improvement over current therapies for autoimmune diseases.MUNICH, Germany, November 30, 2021 / B3C newswire / SciRhom GmbH, a developer of novel antibody therapies, anno. ....

Scirhom Gmb , Andreas Jenne , Jens Ruhe , Scirhom Gmbh , Executive Officer , Rhom Gmbh , High Tech Gruenderfonds , Autoimmune Diseases , Tumor Necrosis Factor Alpha , Intracellular Signaling Peptides , Signal Transduction , Inflammatory Bowel Diseases , Pharmaceutical Preparations , Biological Products ,